Problem

KemNet addresses the gap between standardized commercial drugs and the needs of patients who require more convenient, tolerable, or faster-acting formulations. Medication non-adherence is a central pain point: patients may avoid treatment because of complicated regimens, unpleasant administration, side effects, or slow results. For pharmacies, the problem also has an operational and commercial dimension: drug shortages, fragmented access to compounding labs, regulatory requirements, and the lost margin associated with unmet patient needs all make customized medication fulfillment difficult.

The clearest use case is erectile-dysfunction medication. KemNet says its reformulated products can work up to eight times faster than alternatives, and that more than 30 pharmacies have relied on the company for those products. It also targets reformulations for hair growth, pain, weight loss, beauty, and women’s health, where a more patient-centered formulation could improve adherence while helping pharmacy customers grow their bottom line.

Product / Service

KemNet is a B2B marketplace and pharmacy-technology platform for customized medications—effectively an “Amazon” for personalized drug supply. It connects prescribers, pharmacies, and compounding laboratories so pharmacies can order patient-specific formulations more efficiently. Its software offering is described as covering medication ordering, compounded-drug tracking, regulatory compliance, transparency, and an audit trail for insurance and regulatory purposes.

The model combines technology with access to reformulated medicines rather than asking every pharmacy to compound products itself. In practice, the platform helps pharmacies source specialized medications, manage shortages, and fulfill prescriptions in a compliant way, while patients benefit from formulations designed to work faster, be easier or more enjoyable to use, and potentially produce fewer side effects.

Market

KemNet competes at the intersection of digital health, pharmacy IT, B2B healthcare marketplaces, personalized medicine, and pharmaceutical compounding. Its closest competitive set includes established compounding pharmacies that provide customized medicines directly to pharmacies and clinics, such as Create Compounding, as well as pharmacy-compounding and compliance-software vendors such as Wolters Kluwer’s Simplifi 797. These are partly direct and partly adjacent competitors: some compete for the medication-supply relationship, while others compete for the pharmacy workflow and compliance layer.

The company was founded in Edmonton in 2022 and entered Y Combinator’s Summer 2022 batch. Its reported historical traction includes adoption by more than 30 pharmacies for erectile-dysfunction products, and PitchBook reports $510,000 in total funding, including a $500,000 accelerator round. Current status is less certain: Y Combinator lists KemNet as active and LinkedIn continues to describe the software business, while PitchBook reports it as out of business as of June 2025 and does not provide current revenue. The best-supported conclusion is therefore that KemNet achieved early commercial traction but that its operating status and present-day scale are not independently settled by the available public evidence.